nodes	percent_of_prediction	percent_of_DWPC	metapath
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	0.000805	0.00111	CcSEcCtD
Roflumilast—Ill-defined disorder—Metformin—type 2 diabetes mellitus	0.000804	0.00111	CcSEcCtD
Roflumilast—Tension—Irbesartan—type 2 diabetes mellitus	0.000803	0.00111	CcSEcCtD
Roflumilast—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.000802	0.00111	CcSEcCtD
Roflumilast—Dysgeusia—Irbesartan—type 2 diabetes mellitus	0.000801	0.00111	CcSEcCtD
Roflumilast—Myalgia—Orlistat—type 2 diabetes mellitus	0.000801	0.00111	CcSEcCtD
Roflumilast—Hepatobiliary disease—Ramipril—type 2 diabetes mellitus	0.000799	0.00111	CcSEcCtD
Roflumilast—Anxiety—Orlistat—type 2 diabetes mellitus	0.000798	0.00111	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.000795	0.0011	CcSEcCtD
Roflumilast—Nervousness—Irbesartan—type 2 diabetes mellitus	0.000795	0.0011	CcSEcCtD
Roflumilast—Sinusitis—Ramipril—type 2 diabetes mellitus	0.000793	0.0011	CcSEcCtD
Roflumilast—Discomfort—Orlistat—type 2 diabetes mellitus	0.000791	0.0011	CcSEcCtD
Roflumilast—Muscle spasms—Irbesartan—type 2 diabetes mellitus	0.000787	0.00109	CcSEcCtD
Roflumilast—Malaise—Metformin—type 2 diabetes mellitus	0.000782	0.00108	CcSEcCtD
Roflumilast—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000781	0.00108	CcSEcCtD
Roflumilast—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.000779	0.00108	CcSEcCtD
Roflumilast—Vomiting—Glipizide—type 2 diabetes mellitus	0.000778	0.00108	CcSEcCtD
Roflumilast—Feeling abnormal—Glyburide—type 2 diabetes mellitus	0.000776	0.00107	CcSEcCtD
Roflumilast—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000775	0.00107	CcSEcCtD
Roflumilast—Infection—Valsartan—type 2 diabetes mellitus	0.000772	0.00107	CcSEcCtD
Roflumilast—Rash—Glipizide—type 2 diabetes mellitus	0.000772	0.00107	CcSEcCtD
Roflumilast—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000771	0.00107	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	0.00077	0.00107	CcSEcCtD
Roflumilast—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	0.00077	0.00107	CcSEcCtD
Roflumilast—Headache—Glipizide—type 2 diabetes mellitus	0.000767	0.00106	CcSEcCtD
Roflumilast—Tremor—Irbesartan—type 2 diabetes mellitus	0.000766	0.00106	CcSEcCtD
Roflumilast—Palpitations—Metformin—type 2 diabetes mellitus	0.000766	0.00106	CcSEcCtD
Roflumilast—Insomnia—Gliclazide—type 2 diabetes mellitus	0.000765	0.00106	CcSEcCtD
Roflumilast—Infection—Orlistat—type 2 diabetes mellitus	0.000763	0.00106	CcSEcCtD
Roflumilast—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000762	0.00106	CcSEcCtD
Roflumilast—Ill-defined disorder—Irbesartan—type 2 diabetes mellitus	0.000759	0.00105	CcSEcCtD
Roflumilast—Tension—Losartan—type 2 diabetes mellitus	0.000756	0.00105	CcSEcCtD
Roflumilast—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000755	0.00105	CcSEcCtD
Roflumilast—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000755	0.00105	CcSEcCtD
Roflumilast—Dysgeusia—Losartan—type 2 diabetes mellitus	0.000754	0.00104	CcSEcCtD
Roflumilast—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000753	0.00104	CcSEcCtD
Roflumilast—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000753	0.00104	CcSEcCtD
Roflumilast—Urticaria—Glyburide—type 2 diabetes mellitus	0.000748	0.00104	CcSEcCtD
Roflumilast—Nervousness—Losartan—type 2 diabetes mellitus	0.000748	0.00104	CcSEcCtD
Roflumilast—Angioedema—Irbesartan—type 2 diabetes mellitus	0.000748	0.00104	CcSEcCtD
Roflumilast—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000746	0.00103	CcSEcCtD
Roflumilast—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	0.000745	0.00103	CcSEcCtD
Roflumilast—Back pain—Losartan—type 2 diabetes mellitus	0.000745	0.00103	CcSEcCtD
Roflumilast—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.000744	0.00103	CcSEcCtD
Roflumilast—Dyspepsia—Gliclazide—type 2 diabetes mellitus	0.000744	0.00103	CcSEcCtD
Roflumilast—Muscle spasms—Losartan—type 2 diabetes mellitus	0.00074	0.00103	CcSEcCtD
Roflumilast—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000739	0.00102	CcSEcCtD
Roflumilast—Myalgia—Metformin—type 2 diabetes mellitus	0.000738	0.00102	CcSEcCtD
Roflumilast—Malaise—Irbesartan—type 2 diabetes mellitus	0.000738	0.00102	CcSEcCtD
Roflumilast—Vertigo—Irbesartan—type 2 diabetes mellitus	0.000735	0.00102	CcSEcCtD
Roflumilast—Headache—Pioglitazone—type 2 diabetes mellitus	0.000734	0.00102	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000733	0.00102	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.00073	0.00101	CcSEcCtD
Roflumilast—Discomfort—Metformin—type 2 diabetes mellitus	0.000729	0.00101	CcSEcCtD
Roflumilast—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000729	0.00101	CcSEcCtD
Roflumilast—Nausea—Glipizide—type 2 diabetes mellitus	0.000727	0.00101	CcSEcCtD
Roflumilast—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000726	0.00101	CcSEcCtD
Roflumilast—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000724	0.001	CcSEcCtD
Roflumilast—Constipation—Gliclazide—type 2 diabetes mellitus	0.000723	0.001	CcSEcCtD
Roflumilast—Tremor—Losartan—type 2 diabetes mellitus	0.000721	0.000999	CcSEcCtD
Roflumilast—Rash—Glimepiride—type 2 diabetes mellitus	0.00072	0.000997	CcSEcCtD
Roflumilast—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000719	0.000996	CcSEcCtD
Roflumilast—Rash—Sitagliptin—type 2 diabetes mellitus	0.000718	0.000994	CcSEcCtD
Roflumilast—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000717	0.000993	CcSEcCtD
Roflumilast—Headache—Glimepiride—type 2 diabetes mellitus	0.000715	0.000991	CcSEcCtD
Roflumilast—Ill-defined disorder—Losartan—type 2 diabetes mellitus	0.000714	0.000989	CcSEcCtD
Roflumilast—Headache—Sitagliptin—type 2 diabetes mellitus	0.000713	0.000988	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.000708	0.00098	CcSEcCtD
Roflumilast—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000705	0.000976	CcSEcCtD
Roflumilast—Angioedema—Losartan—type 2 diabetes mellitus	0.000704	0.000974	CcSEcCtD
Roflumilast—Infection—Metformin—type 2 diabetes mellitus	0.000703	0.000973	CcSEcCtD
Roflumilast—Insomnia—Valsartan—type 2 diabetes mellitus	0.000703	0.000973	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000699	0.000969	CcSEcCtD
Roflumilast—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000697	0.000965	CcSEcCtD
Roflumilast—Myalgia—Irbesartan—type 2 diabetes mellitus	0.000697	0.000965	CcSEcCtD
Roflumilast—Insomnia—Orlistat—type 2 diabetes mellitus	0.000694	0.000962	CcSEcCtD
Roflumilast—Malaise—Losartan—type 2 diabetes mellitus	0.000694	0.000962	CcSEcCtD
Roflumilast—Anxiety—Irbesartan—type 2 diabetes mellitus	0.000694	0.000961	CcSEcCtD
Roflumilast—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000694	0.000961	CcSEcCtD
Roflumilast—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000694	0.000961	CcSEcCtD
Roflumilast—Vertigo—Losartan—type 2 diabetes mellitus	0.000692	0.000958	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000692	0.000958	CcSEcCtD
Roflumilast—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000692	0.000958	CcSEcCtD
Roflumilast—Discomfort—Irbesartan—type 2 diabetes mellitus	0.000688	0.000953	CcSEcCtD
Roflumilast—Skin disorder—Metformin—type 2 diabetes mellitus	0.000687	0.000952	CcSEcCtD
Roflumilast—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.000685	0.000949	CcSEcCtD
Roflumilast—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000684	0.000947	CcSEcCtD
Roflumilast—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000683	0.000947	CcSEcCtD
Roflumilast—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000681	0.000943	CcSEcCtD
Roflumilast—Palpitations—Losartan—type 2 diabetes mellitus	0.00068	0.000942	CcSEcCtD
Roflumilast—Nausea—Glimepiride—type 2 diabetes mellitus	0.000678	0.000939	CcSEcCtD
Roflumilast—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000676	0.000936	CcSEcCtD
Roflumilast—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.000676	0.000936	CcSEcCtD
Roflumilast—Asthenia—Glyburide—type 2 diabetes mellitus	0.000676	0.000936	CcSEcCtD
Roflumilast—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000675	0.000935	CcSEcCtD
Roflumilast—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000672	0.00093	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000671	0.000929	CcSEcCtD
Roflumilast—Fatigue—Valsartan—type 2 diabetes mellitus	0.00067	0.000928	CcSEcCtD
Roflumilast—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000668	0.000926	CcSEcCtD
Roflumilast—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.000667	0.000924	CcSEcCtD
Roflumilast—Mental disorder—Ramipril—type 2 diabetes mellitus	0.000664	0.00092	CcSEcCtD
Roflumilast—Constipation—Valsartan—type 2 diabetes mellitus	0.000664	0.00092	CcSEcCtD
Roflumilast—Infection—Irbesartan—type 2 diabetes mellitus	0.000663	0.000919	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000663	0.000918	CcSEcCtD
Roflumilast—Fatigue—Orlistat—type 2 diabetes mellitus	0.000662	0.000917	CcSEcCtD
Roflumilast—Malnutrition—Ramipril—type 2 diabetes mellitus	0.00066	0.000914	CcSEcCtD
Roflumilast—Myalgia—Losartan—type 2 diabetes mellitus	0.000655	0.000908	CcSEcCtD
Roflumilast—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000655	0.000907	CcSEcCtD
Roflumilast—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000655	0.000907	CcSEcCtD
Roflumilast—Anxiety—Losartan—type 2 diabetes mellitus	0.000653	0.000905	CcSEcCtD
Roflumilast—Rash—Bromocriptine—type 2 diabetes mellitus	0.00065	0.0009	CcSEcCtD
Roflumilast—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000649	0.000899	CcSEcCtD
Roflumilast—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000649	0.000898	CcSEcCtD
Roflumilast—Tension—Ramipril—type 2 diabetes mellitus	0.000648	0.000897	CcSEcCtD
Roflumilast—Discomfort—Losartan—type 2 diabetes mellitus	0.000648	0.000897	CcSEcCtD
Roflumilast—Dysgeusia—Ramipril—type 2 diabetes mellitus	0.000646	0.000895	CcSEcCtD
Roflumilast—Headache—Bromocriptine—type 2 diabetes mellitus	0.000645	0.000894	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000645	0.000893	CcSEcCtD
Roflumilast—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000644	0.000892	CcSEcCtD
Roflumilast—Nervousness—Ramipril—type 2 diabetes mellitus	0.000641	0.000888	CcSEcCtD
Roflumilast—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.000635	0.00088	CcSEcCtD
Roflumilast—Muscle spasms—Ramipril—type 2 diabetes mellitus	0.000635	0.000879	CcSEcCtD
Roflumilast—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.000633	0.000876	CcSEcCtD
Roflumilast—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.000628	0.000869	CcSEcCtD
Roflumilast—Infection—Losartan—type 2 diabetes mellitus	0.000624	0.000865	CcSEcCtD
Roflumilast—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000623	0.000863	CcSEcCtD
Roflumilast—Dyspepsia—Metformin—type 2 diabetes mellitus	0.000623	0.000863	CcSEcCtD
Roflumilast—Tremor—Ramipril—type 2 diabetes mellitus	0.000619	0.000857	CcSEcCtD
Roflumilast—Urticaria—Valsartan—type 2 diabetes mellitus	0.000617	0.000855	CcSEcCtD
Roflumilast—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000616	0.000853	CcSEcCtD
Roflumilast—Decreased appetite—Metformin—type 2 diabetes mellitus	0.000615	0.000852	CcSEcCtD
Roflumilast—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000614	0.000851	CcSEcCtD
Roflumilast—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	0.000613	0.000848	CcSEcCtD
Roflumilast—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000612	0.000847	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000611	0.000846	CcSEcCtD
Roflumilast—Fatigue—Metformin—type 2 diabetes mellitus	0.00061	0.000845	CcSEcCtD
Roflumilast—Urticaria—Orlistat—type 2 diabetes mellitus	0.00061	0.000845	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000608	0.000842	CcSEcCtD
Roflumilast—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.000607	0.000841	CcSEcCtD
Roflumilast—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000607	0.00084	CcSEcCtD
Roflumilast—Constipation—Metformin—type 2 diabetes mellitus	0.000605	0.000838	CcSEcCtD
Roflumilast—Angioedema—Ramipril—type 2 diabetes mellitus	0.000603	0.000835	CcSEcCtD
Roflumilast—Vomiting—Glyburide—type 2 diabetes mellitus	0.000599	0.000829	CcSEcCtD
Roflumilast—Malaise—Ramipril—type 2 diabetes mellitus	0.000595	0.000825	CcSEcCtD
Roflumilast—Rash—Glyburide—type 2 diabetes mellitus	0.000594	0.000822	CcSEcCtD
Roflumilast—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000593	0.000822	CcSEcCtD
Roflumilast—Vertigo—Ramipril—type 2 diabetes mellitus	0.000593	0.000821	CcSEcCtD
Roflumilast—Headache—Glyburide—type 2 diabetes mellitus	0.00059	0.000817	CcSEcCtD
Roflumilast—Dyspepsia—Irbesartan—type 2 diabetes mellitus	0.000588	0.000814	CcSEcCtD
Roflumilast—Palpitations—Ramipril—type 2 diabetes mellitus	0.000583	0.000808	CcSEcCtD
Roflumilast—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.000583	0.000807	CcSEcCtD
Roflumilast—Decreased appetite—Irbesartan—type 2 diabetes mellitus	0.00058	0.000804	CcSEcCtD
Roflumilast—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000579	0.000801	CcSEcCtD
Roflumilast—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.000579	0.000801	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000576	0.000798	CcSEcCtD
Roflumilast—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000576	0.000797	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.000572	0.000793	CcSEcCtD
Roflumilast—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000572	0.000793	CcSEcCtD
Roflumilast—Constipation—Irbesartan—type 2 diabetes mellitus	0.000571	0.000791	CcSEcCtD
Roflumilast—Insomnia—Losartan—type 2 diabetes mellitus	0.000568	0.000787	CcSEcCtD
Roflumilast—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000566	0.000783	CcSEcCtD
Roflumilast—Urticaria—Metformin—type 2 diabetes mellitus	0.000562	0.000778	CcSEcCtD
Roflumilast—Myalgia—Ramipril—type 2 diabetes mellitus	0.000562	0.000778	CcSEcCtD
Roflumilast—Anxiety—Ramipril—type 2 diabetes mellitus	0.00056	0.000776	CcSEcCtD
Roflumilast—Nausea—Glyburide—type 2 diabetes mellitus	0.000559	0.000775	CcSEcCtD
Roflumilast—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000559	0.000775	CcSEcCtD
Roflumilast—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000559	0.000774	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000558	0.000773	CcSEcCtD
Roflumilast—Asthenia—Valsartan—type 2 diabetes mellitus	0.000557	0.000772	CcSEcCtD
Roflumilast—Discomfort—Ramipril—type 2 diabetes mellitus	0.000555	0.000769	CcSEcCtD
Roflumilast—Dyspepsia—Losartan—type 2 diabetes mellitus	0.000553	0.000766	CcSEcCtD
Roflumilast—Asthenia—Orlistat—type 2 diabetes mellitus	0.000551	0.000763	CcSEcCtD
Roflumilast—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.00055	0.000762	CcSEcCtD
Roflumilast—Decreased appetite—Losartan—type 2 diabetes mellitus	0.000546	0.000757	CcSEcCtD
Roflumilast—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.000546	0.000756	CcSEcCtD
Roflumilast—Fatigue—Losartan—type 2 diabetes mellitus	0.000542	0.00075	CcSEcCtD
Roflumilast—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000538	0.000745	CcSEcCtD
Roflumilast—Constipation—Losartan—type 2 diabetes mellitus	0.000537	0.000744	CcSEcCtD
Roflumilast—Rash—Gliclazide—type 2 diabetes mellitus	0.000533	0.000738	CcSEcCtD
Roflumilast—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000533	0.000738	CcSEcCtD
Roflumilast—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000532	0.000736	CcSEcCtD
Roflumilast—Urticaria—Irbesartan—type 2 diabetes mellitus	0.00053	0.000735	CcSEcCtD
Roflumilast—Headache—Gliclazide—type 2 diabetes mellitus	0.00053	0.000734	CcSEcCtD
Roflumilast—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000528	0.000732	CcSEcCtD
Roflumilast—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.000528	0.000731	CcSEcCtD
Roflumilast—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000525	0.000727	CcSEcCtD
Roflumilast—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000523	0.000725	CcSEcCtD
Roflumilast—Feeling abnormal—Losartan—type 2 diabetes mellitus	0.000518	0.000717	CcSEcCtD
Roflumilast—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.000514	0.000712	CcSEcCtD
Roflumilast—Dizziness—Valsartan—type 2 diabetes mellitus	0.000514	0.000712	CcSEcCtD
Roflumilast—Dizziness—Orlistat—type 2 diabetes mellitus	0.000508	0.000703	CcSEcCtD
Roflumilast—Asthenia—Metformin—type 2 diabetes mellitus	0.000508	0.000703	CcSEcCtD
Roflumilast—Nausea—Gliclazide—type 2 diabetes mellitus	0.000502	0.000696	CcSEcCtD
Roflumilast—Urticaria—Losartan—type 2 diabetes mellitus	0.000499	0.000691	CcSEcCtD
Roflumilast—Abdominal pain—Losartan—type 2 diabetes mellitus	0.000497	0.000688	CcSEcCtD
Roflumilast—Vomiting—Valsartan—type 2 diabetes mellitus	0.000494	0.000684	CcSEcCtD
Roflumilast—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000492	0.000681	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	0.000491	0.00068	CcSEcCtD
Roflumilast—Rash—Valsartan—type 2 diabetes mellitus	0.00049	0.000678	CcSEcCtD
Roflumilast—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000489	0.000678	CcSEcCtD
Roflumilast—Vomiting—Orlistat—type 2 diabetes mellitus	0.000488	0.000676	CcSEcCtD
Roflumilast—Insomnia—Ramipril—type 2 diabetes mellitus	0.000487	0.000675	CcSEcCtD
Roflumilast—Headache—Valsartan—type 2 diabetes mellitus	0.000487	0.000674	CcSEcCtD
Roflumilast—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000484	0.00067	CcSEcCtD
Roflumilast—Rash—Orlistat—type 2 diabetes mellitus	0.000484	0.00067	CcSEcCtD
Roflumilast—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000484	0.00067	CcSEcCtD
Roflumilast—Headache—Orlistat—type 2 diabetes mellitus	0.000481	0.000666	CcSEcCtD
Roflumilast—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000479	0.000663	CcSEcCtD
Roflumilast—Dyspepsia—Ramipril—type 2 diabetes mellitus	0.000474	0.000657	CcSEcCtD
Roflumilast—Decreased appetite—Ramipril—type 2 diabetes mellitus	0.000468	0.000649	CcSEcCtD
Roflumilast—Dizziness—Metformin—type 2 diabetes mellitus	0.000468	0.000648	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000465	0.000644	CcSEcCtD
Roflumilast—Fatigue—Ramipril—type 2 diabetes mellitus	0.000465	0.000643	CcSEcCtD
Roflumilast—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.000463	0.000641	CcSEcCtD
Roflumilast—Nausea—Valsartan—type 2 diabetes mellitus	0.000461	0.000639	CcSEcCtD
Roflumilast—Constipation—Ramipril—type 2 diabetes mellitus	0.000461	0.000638	CcSEcCtD
Roflumilast—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000457	0.000633	CcSEcCtD
Roflumilast—Nausea—Orlistat—type 2 diabetes mellitus	0.000456	0.000632	CcSEcCtD
Roflumilast—Asthenia—Losartan—type 2 diabetes mellitus	0.000451	0.000624	CcSEcCtD
Roflumilast—Vomiting—Metformin—type 2 diabetes mellitus	0.00045	0.000623	CcSEcCtD
Roflumilast—Rash—Metformin—type 2 diabetes mellitus	0.000446	0.000618	CcSEcCtD
Roflumilast—Dermatitis—Metformin—type 2 diabetes mellitus	0.000446	0.000617	CcSEcCtD
Roflumilast—Feeling abnormal—Ramipril—type 2 diabetes mellitus	0.000444	0.000615	CcSEcCtD
Roflumilast—Headache—Metformin—type 2 diabetes mellitus	0.000443	0.000614	CcSEcCtD
Roflumilast—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000442	0.000611	CcSEcCtD
Roflumilast—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	0.000441	0.00061	CcSEcCtD
Roflumilast—Diarrhoea—Losartan—type 2 diabetes mellitus	0.00043	0.000595	CcSEcCtD
Roflumilast—Urticaria—Ramipril—type 2 diabetes mellitus	0.000428	0.000593	CcSEcCtD
Roflumilast—Abdominal pain—Ramipril—type 2 diabetes mellitus	0.000426	0.00059	CcSEcCtD
Roflumilast—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000425	0.000588	CcSEcCtD
Roflumilast—Rash—Irbesartan—type 2 diabetes mellitus	0.000421	0.000583	CcSEcCtD
Roflumilast—Dermatitis—Irbesartan—type 2 diabetes mellitus	0.000421	0.000583	CcSEcCtD
Roflumilast—Nausea—Metformin—type 2 diabetes mellitus	0.00042	0.000582	CcSEcCtD
Roflumilast—Headache—Irbesartan—type 2 diabetes mellitus	0.000418	0.000579	CcSEcCtD
Roflumilast—Dizziness—Losartan—type 2 diabetes mellitus	0.000416	0.000575	CcSEcCtD
Roflumilast—Vomiting—Losartan—type 2 diabetes mellitus	0.0004	0.000553	CcSEcCtD
Roflumilast—Hypersensitivity—Ramipril—type 2 diabetes mellitus	0.000397	0.00055	CcSEcCtD
Roflumilast—Nausea—Irbesartan—type 2 diabetes mellitus	0.000397	0.000549	CcSEcCtD
Roflumilast—Rash—Losartan—type 2 diabetes mellitus	0.000396	0.000549	CcSEcCtD
Roflumilast—Dermatitis—Losartan—type 2 diabetes mellitus	0.000396	0.000548	CcSEcCtD
Roflumilast—Headache—Losartan—type 2 diabetes mellitus	0.000394	0.000545	CcSEcCtD
Roflumilast—Asthenia—Ramipril—type 2 diabetes mellitus	0.000387	0.000535	CcSEcCtD
Roflumilast—Nausea—Losartan—type 2 diabetes mellitus	0.000373	0.000517	CcSEcCtD
Roflumilast—Diarrhoea—Ramipril—type 2 diabetes mellitus	0.000369	0.000511	CcSEcCtD
Roflumilast—Dizziness—Ramipril—type 2 diabetes mellitus	0.000356	0.000493	CcSEcCtD
Roflumilast—Vomiting—Ramipril—type 2 diabetes mellitus	0.000343	0.000474	CcSEcCtD
Roflumilast—Rash—Ramipril—type 2 diabetes mellitus	0.00034	0.00047	CcSEcCtD
Roflumilast—Dermatitis—Ramipril—type 2 diabetes mellitus	0.000339	0.00047	CcSEcCtD
Roflumilast—Headache—Ramipril—type 2 diabetes mellitus	0.000338	0.000467	CcSEcCtD
Roflumilast—Nausea—Ramipril—type 2 diabetes mellitus	0.00032	0.000443	CcSEcCtD
Roflumilast—PDE4D—Signaling Pathways—EDNRA—type 2 diabetes mellitus	0.00013	0.000466	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—INSR—type 2 diabetes mellitus	0.000129	0.000465	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CALM1—type 2 diabetes mellitus	0.000129	0.000464	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CYBA—type 2 diabetes mellitus	0.000129	0.000464	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—AGT—type 2 diabetes mellitus	0.000127	0.000458	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	0.000127	0.000457	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TRPC6—type 2 diabetes mellitus	0.000127	0.000457	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	0.000127	0.000456	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—HTR2C—type 2 diabetes mellitus	0.000127	0.000456	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PSMD6—type 2 diabetes mellitus	0.000127	0.000456	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	0.000127	0.000456	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—GHRL—type 2 diabetes mellitus	0.000126	0.000454	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PLAT—type 2 diabetes mellitus	0.000126	0.000454	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—AGTR2—type 2 diabetes mellitus	0.000126	0.000454	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—AGT—type 2 diabetes mellitus	0.000125	0.000449	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CALCA—type 2 diabetes mellitus	0.000125	0.000449	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CCR5—type 2 diabetes mellitus	0.000125	0.000448	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—CCL2—type 2 diabetes mellitus	0.000124	0.000447	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—EDNRA—type 2 diabetes mellitus	0.000123	0.000444	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CALM1—type 2 diabetes mellitus	0.000123	0.000442	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CYBA—type 2 diabetes mellitus	0.000123	0.000442	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—AKT2—type 2 diabetes mellitus	0.000122	0.000439	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	0.000122	0.000438	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—C3—type 2 diabetes mellitus	0.000122	0.000438	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	0.000121	0.000436	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—EDNRB—type 2 diabetes mellitus	0.000121	0.000435	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	0.000121	0.000434	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PLAT—type 2 diabetes mellitus	0.00012	0.000432	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—GHRL—type 2 diabetes mellitus	0.00012	0.000432	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CALCA—type 2 diabetes mellitus	0.000119	0.000427	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	0.000118	0.000423	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	0.000117	0.000423	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—HTR2C—type 2 diabetes mellitus	0.000117	0.000422	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PSMD6—type 2 diabetes mellitus	0.000117	0.000422	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	0.000117	0.000421	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—AGT—type 2 diabetes mellitus	0.000116	0.000416	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—GCG—type 2 diabetes mellitus	0.000116	0.000416	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PTPN1—type 2 diabetes mellitus	0.000116	0.000416	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	0.000115	0.000415	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	0.000115	0.000415	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—GNB3—type 2 diabetes mellitus	0.000114	0.000411	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—EDNRA—type 2 diabetes mellitus	0.000114	0.000411	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CALM1—type 2 diabetes mellitus	0.000114	0.000409	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	0.000114	0.000409	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CYBA—type 2 diabetes mellitus	0.000114	0.000409	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	0.000113	0.000408	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—AVP—type 2 diabetes mellitus	0.000113	0.000406	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MMP3—type 2 diabetes mellitus	0.000113	0.000406	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IGF2—type 2 diabetes mellitus	0.000112	0.000404	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	0.000112	0.000402	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	0.000112	0.000402	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	0.000112	0.000402	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	0.000111	0.0004	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PLAT—type 2 diabetes mellitus	0.000111	0.0004	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—GHRL—type 2 diabetes mellitus	0.000111	0.0004	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	0.000111	0.000398	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PTPN1—type 2 diabetes mellitus	0.00011	0.000396	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—GCG—type 2 diabetes mellitus	0.00011	0.000396	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CALCA—type 2 diabetes mellitus	0.00011	0.000395	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—APOB—type 2 diabetes mellitus	0.000109	0.000392	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IGF1R—type 2 diabetes mellitus	0.000109	0.000391	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	0.000108	0.000389	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CCL2—type 2 diabetes mellitus	0.000108	0.000389	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	0.000108	0.000388	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—EDN1—type 2 diabetes mellitus	0.000107	0.000386	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	0.000107	0.000384	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—AKT2—type 2 diabetes mellitus	0.000106	0.000382	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	0.000106	0.000382	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—LPL—type 2 diabetes mellitus	0.000104	0.000375	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	0.000103	0.000372	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	0.000103	0.000371	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	0.000103	0.00037	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—ADCY5—type 2 diabetes mellitus	0.000102	0.000367	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PTPN1—type 2 diabetes mellitus	0.000102	0.000366	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—GCG—type 2 diabetes mellitus	0.000102	0.000366	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	0.000101	0.000364	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	0.000101	0.000363	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	0.0001	0.000362	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	0.0001	0.00036	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	9.98e-05	0.000359	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—GNB3—type 2 diabetes mellitus	9.96e-05	0.000358	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—AVP—type 2 diabetes mellitus	9.82e-05	0.000353	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MMP3—type 2 diabetes mellitus	9.82e-05	0.000353	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IGF2—type 2 diabetes mellitus	9.78e-05	0.000352	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	9.77e-05	0.000351	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	9.74e-05	0.00035	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	9.64e-05	0.000347	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CCR5—type 2 diabetes mellitus	9.59e-05	0.000345	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	9.56e-05	0.000344	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CCL2—type 2 diabetes mellitus	9.52e-05	0.000343	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—APOB—type 2 diabetes mellitus	9.49e-05	0.000342	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—GNB3—type 2 diabetes mellitus	9.48e-05	0.000341	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IGF1R—type 2 diabetes mellitus	9.45e-05	0.00034	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—C3—type 2 diabetes mellitus	9.37e-05	0.000337	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—AKT2—type 2 diabetes mellitus	9.35e-05	0.000336	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—AVP—type 2 diabetes mellitus	9.35e-05	0.000336	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MMP3—type 2 diabetes mellitus	9.35e-05	0.000336	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	9.34e-05	0.000336	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—EDN1—type 2 diabetes mellitus	9.34e-05	0.000336	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IGF2—type 2 diabetes mellitus	9.31e-05	0.000335	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	9.27e-05	0.000333	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	9.17e-05	0.00033	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—LPL—type 2 diabetes mellitus	9.06e-05	0.000326	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—APOB—type 2 diabetes mellitus	9.04e-05	0.000325	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	9e-05	0.000324	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—HIF1A—type 2 diabetes mellitus	8.94e-05	0.000322	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IRS2—type 2 diabetes mellitus	8.92e-05	0.000321	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—AGT—type 2 diabetes mellitus	8.91e-05	0.00032	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—EDN1—type 2 diabetes mellitus	8.89e-05	0.00032	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—ADCY5—type 2 diabetes mellitus	8.87e-05	0.000319	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	8.85e-05	0.000318	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—GNB3—type 2 diabetes mellitus	8.77e-05	0.000315	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CALM1—type 2 diabetes mellitus	8.76e-05	0.000315	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—LEP—type 2 diabetes mellitus	8.73e-05	0.000314	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—APOE—type 2 diabetes mellitus	8.73e-05	0.000314	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—AVP—type 2 diabetes mellitus	8.65e-05	0.000311	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MMP3—type 2 diabetes mellitus	8.65e-05	0.000311	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—LPL—type 2 diabetes mellitus	8.63e-05	0.00031	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—APOA1—type 2 diabetes mellitus	8.63e-05	0.00031	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IGF2—type 2 diabetes mellitus	8.61e-05	0.00031	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	8.57e-05	0.000308	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.5e-05	0.000306	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	8.49e-05	0.000305	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	8.45e-05	0.000304	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—APOB—type 2 diabetes mellitus	8.36e-05	0.000301	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.35e-05	0.0003	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IGF1R—type 2 diabetes mellitus	8.33e-05	0.0003	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PRKCB—type 2 diabetes mellitus	8.23e-05	0.000296	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—EDN1—type 2 diabetes mellitus	8.23e-05	0.000296	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—C3—type 2 diabetes mellitus	8.16e-05	0.000294	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.09e-05	0.000291	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—LPL—type 2 diabetes mellitus	7.98e-05	0.000287	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CCR5—type 2 diabetes mellitus	7.95e-05	0.000286	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ADCY5—type 2 diabetes mellitus	7.82e-05	0.000281	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IRS1—type 2 diabetes mellitus	7.79e-05	0.00028	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—HIF1A—type 2 diabetes mellitus	7.78e-05	0.00028	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—C3—type 2 diabetes mellitus	7.77e-05	0.000279	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.76e-05	0.000279	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—AGT—type 2 diabetes mellitus	7.75e-05	0.000279	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.62e-05	0.000274	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—APOE—type 2 diabetes mellitus	7.6e-05	0.000273	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—LEP—type 2 diabetes mellitus	7.6e-05	0.000273	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.51e-05	0.00027	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	7.49e-05	0.000269	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—INS—type 2 diabetes mellitus	7.46e-05	0.000268	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	7.41e-05	0.000267	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.39e-05	0.000266	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—AGT—type 2 diabetes mellitus	7.38e-05	0.000266	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CCR5—type 2 diabetes mellitus	7.36e-05	0.000265	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.34e-05	0.000264	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.26e-05	0.000261	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—LEP—type 2 diabetes mellitus	7.23e-05	0.00026	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—APOE—type 2 diabetes mellitus	7.23e-05	0.00026	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.21e-05	0.000259	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.21e-05	0.000259	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—C3—type 2 diabetes mellitus	7.19e-05	0.000259	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—EGFR—type 2 diabetes mellitus	7.18e-05	0.000258	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7.16e-05	0.000258	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.15e-05	0.000257	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—HIF1A—type 2 diabetes mellitus	6.85e-05	0.000247	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.85e-05	0.000246	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IRS2—type 2 diabetes mellitus	6.84e-05	0.000246	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—AGT—type 2 diabetes mellitus	6.83e-05	0.000246	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	6.82e-05	0.000245	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.78e-05	0.000244	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CALM1—type 2 diabetes mellitus	6.72e-05	0.000242	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—LEP—type 2 diabetes mellitus	6.69e-05	0.000241	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—APOE—type 2 diabetes mellitus	6.69e-05	0.000241	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—APOA1—type 2 diabetes mellitus	6.61e-05	0.000238	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.54e-05	0.000235	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.54e-05	0.000235	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—INS—type 2 diabetes mellitus	6.49e-05	0.000234	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.45e-05	0.000232	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.39e-05	0.00023	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PRKCB—type 2 diabetes mellitus	6.31e-05	0.000227	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.28e-05	0.000226	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.27e-05	0.000226	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.25e-05	0.000225	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—INS—type 2 diabetes mellitus	6.18e-05	0.000222	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—RELA—type 2 diabetes mellitus	6.15e-05	0.000221	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.08e-05	0.000219	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.98e-05	0.000215	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.97e-05	0.000215	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IRS1—type 2 diabetes mellitus	5.97e-05	0.000215	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.96e-05	0.000214	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	5.95e-05	0.000214	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—INS—type 2 diabetes mellitus	5.72e-05	0.000206	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.69e-05	0.000205	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.69e-05	0.000205	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.67e-05	0.000204	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.62e-05	0.000202	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.6e-05	0.000202	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.55e-05	0.0002	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.53e-05	0.000199	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.53e-05	0.000199	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.52e-05	0.000198	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	5.5e-05	0.000198	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.42e-05	0.000195	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.42e-05	0.000195	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—RELA—type 2 diabetes mellitus	5.36e-05	0.000193	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.25e-05	0.000189	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.25e-05	0.000189	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.19e-05	0.000187	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—RELA—type 2 diabetes mellitus	5.1e-05	0.000183	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.09e-05	0.000183	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.01e-05	0.00018	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.01e-05	0.00018	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.88e-05	0.000175	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—SRC—type 2 diabetes mellitus	4.84e-05	0.000174	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.83e-05	0.000174	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.8e-05	0.000173	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—RELA—type 2 diabetes mellitus	4.72e-05	0.00017	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.71e-05	0.000169	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.64e-05	0.000167	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.6e-05	0.000165	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.57e-05	0.000164	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.57e-05	0.000164	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.52e-05	0.000163	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.43e-05	0.000159	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.35e-05	0.000156	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.32e-05	0.000156	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.3e-05	0.000155	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.3e-05	0.000155	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.26e-05	0.000153	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.24e-05	0.000153	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.23e-05	0.000152	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.22e-05	0.000152	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—SRC—type 2 diabetes mellitus	4.21e-05	0.000151	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.1e-05	0.000148	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.02e-05	0.000145	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—SRC—type 2 diabetes mellitus	4.01e-05	0.000144	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.98e-05	0.000143	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.9e-05	0.00014	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.9e-05	0.00014	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.76e-05	0.000135	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—SRC—type 2 diabetes mellitus	3.71e-05	0.000133	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.69e-05	0.000133	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.61e-05	0.00013	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.58e-05	0.000129	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.51e-05	0.000126	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.31e-05	0.000119	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IL6—type 2 diabetes mellitus	3.26e-05	0.000117	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.25e-05	0.000117	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.01e-05	0.000108	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IL6—type 2 diabetes mellitus	2.84e-05	0.000102	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IL6—type 2 diabetes mellitus	2.7e-05	9.71e-05	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.62e-05	9.41e-05	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IL6—type 2 diabetes mellitus	2.5e-05	8.99e-05	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.49e-05	8.96e-05	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.3e-05	8.29e-05	CbGpPWpGaD
